Appendix Table E32. Phenotypic test details in studies assessing the predictive ability of VerifyNow in patients with cerebrovascular disease

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Author, year [ref]**  **UID**  **Country**  **Study Name** | **Test/Device name**  **Device category Device name & manufacturer\*** | **Agonist used** | **Sample Collection and Procurement**  **Anticoagulant used**  **Interval between clopidogrel doses and blood sampling (in days)**  **Interval between sampling and testing (in days):** | **Grouping of Phenotypes\*\* [Definition]** | **Rational for the grouping of phenotypes reported (Yes/No)**  **[short description]** | **Frequency of phenotypes** |
| Ryu, 2010  21113358  South Korea  NR | VerifyNow P2Y12 assay  NR  Accumetrics Inc | NR | NR  NR  Test conducted after taking the medicine for 3 days  NR | platelet inhibition < 40% (clopidogrel resistance)  platelet inhibition >/= 40% (clopidogrel nonresistance) | Not explicitly reported. | platelet inhibition < 40% (clopidogrel resistance): 33/53 (62.3%)  platelet inhibition >/= 40% (clopidogrel nonresistance): 20/53 (37.7%) |
| Kang, 2010  20223886  South Korea  NR | VerifyNow P2Y12 assay/Turbidimetric based  optical detection system  VerifyNow P2Y12 assay  Accumetrics, San Diego, California | 20 μmol of ADP | Whole blood was obtained before the coil embolization  3.2% sodium citrate  NR [Clopidogrel came first]  NR | First quartile (<240 PRU)  Second quartile (240-284 PRU)  Third quartile (285-332 PRU) Fourth quartile (>332 PRU) | Not explicitly reported. | First quartile (<240 PRU): 47 (25.3%)  Second quartile (240-284 PRU): 46 (24.7%)  Third quartile (285-332 PRU): 46 (24.7%)  Fourth quartile (>332 PRU): 47 (25.3%) |
| Drazin, 2011  21990814  US  NR | VerifyNowP2Y12assay  NR  Accumetrics | ADP | NR  Heparin  Clopidogrel given at least 12 hr before stenting and measurements taken intraoperatively  NR | Suboptimal clopidogrel response (<20% P2Y12 platelet inhibition), measured intraoperatively  Optimal responders, measured intraoperatively | Not explicitly reported. | Suboptimal clopidogrel response (<20% P2Y12 platelet inhibition), measured intraoperatively: 19/52 (37%)  Optimal responders, measured intraoperatively: 33/52 (63%) |

**Abbreviations:** ADP= adenosine 5’-diphosphate; Ag= aggregation; PGE1=prostaglandin; ROC=receiver operating characteristic; AUC=area under the curve; IPA= inhibition of platelet aggregation; LTA= light transmission aggregometry; MEA= multiple electrode platelet aggregometry; PFA= platelet function analysis; TEG=thromboelastography; sTEG=short thromboelastography; VASP = vasodilator-stimulated phosphoprotein; VASP-FCT=vasodilator-stimulated phosphoprotein flow cytometry; CEPI=collagen-epinephrine ; CADP=collagen-ADP; CT=closure times; HCPR=high on-clopidogrel platelet reactivity; PCI = percutaneous coronary intervention; RPA= residual platelet aggregation; GP= glycoprotein; HRP=high platelet reactivity; NPR=normal on-treatment platelet reactivity; HPPR= high post-treatment platelet reactivity; MPA= maximum platelet aggregation; RPR= residual platelet reactivity; OTPR=on-treatment platelet reactivity; DPAI= degree of platelet aggregation inhibition; PRU=P2Y12 reaction units; CRP=C-reaction protein; PRI=platelet reactivity index; LR=low responder; IQR=interquartile range; AA= arachidonic acid; LD=loading dose; MD=maintain dose; SD=standard deviation; NR=not reported